Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease.
- 1 March 2001
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 3 (2) , 139-148
- https://doi.org/10.1007/s11883-001-0050-7
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2000
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Glycoprotein IIb/IIIa Receptor Inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into PerspectiveThe American Journal of Cardiology, 1996
- Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIbIIIa integrin receptorAmerican Heart Journal, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy: Results of the thrombolysis and angioplasty in mycardial infaraction (TAMI) 8 pilot studyJournal of the American College of Cardiology, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Integrins: A family of cell surface receptorsCell, 1987
- Arg-Gly-Asp: A versatile cell recognition signalCell, 1986